Tocilizumab monotherapy uncovered the role of the CCL22/17‐CCR4(+) Treg axis during remission of crescentic glomerulonephritis

OBJECTIVES: Tocilizumab (TCZ) is a humanised anti‐interleukin (IL)‐6 receptor (IL‐6R) monoclonal antibody that is a promising agent to treat various autoimmune diseases. However, the mechanism of TCZ efficacy is unclear. This study aims to elucidate the relationship between Tregs and IL‐6R blockade...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Ryota, Ito, Minako, Yoshimoto, Keiko, Chikuma, Shunsuke, Kurasawa, Takahiko, Kondo, Tsuneo, Suzuki, Katsuya, Takeuchi, Tsutomu, Amano, Koichi, Yoshimura, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596393/
https://www.ncbi.nlm.nih.gov/pubmed/33163184
http://dx.doi.org/10.1002/cti2.1203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596393/
https://www.ncbi.nlm.nih.gov/pubmed/33163184
http://dx.doi.org/10.1002/cti2.1203

Ejemplares similares